Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Colorectal Cancer

    US Partner

    An Introduction to Colorectal Cancer

    Colorectal cancer (CRC) is the third leading cause of cancer death worldwide. The mainstay of treatment for advanced disease is chemotherapy combined with angiogenesis inhibitors and epidermal growth factor receptor (EGFR) inhibitors, but outcomes and toxicity are highly variable. Recent advances include combined small molecule/monoclonal antibody therapies for CRC with the V600E mutation in the BRAF gene for metastatic disease and immune checkpoint inhibition.

    Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Colorectal Cancer Content

    Colorectal Cancer
    3D rendered Medical Illustration of Male Anatomy - Rectal Cancer.
    Trifluridine/Tipiracil and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer
    Gabriel Valagni, Nkafu Bechem Ndemazie, Tiago Biachi de Castria

    touchREVIEWS in Oncology & Haematology. 2024;20(2):Online ahead of journal publication

    Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 It was first identified by Callahan et al. in 1996 as an active impurity in the herbicide trifluralin, which […]

    Colorectal Cancer, Gastrointestinal Cancers
    Project Cure CRC pushes for cutting-edge innovations in colorectal cancer care

    Colorectal cancer is the third most common cancer worldwide and is the second leading cause of cancer-related deaths for men and women combined. The disease is on the rise in younger generations. It is the leading cause of cancer-related deaths in men under 50, and researchers predict it will become the leading cause in men and women ages 20-49 within the next decade. However, it remains less known and less funded than other cancers. For comparison, breast cancer, which has benefited greatly from major funding that contributed to significant research advancements, has a five-year survival rate of 30%, whereas the five-year survival rate for colorectal cancer is drastically lower at only 13%. To achieve better outcomes, the Colorectal Cancer Alliance (Alliance) is reinvigorating its mission to end colorectal cancer with the launch of Project Cure CRC.

    Breast Cancer, Colorectal Cancer, Gastrointestinal Cancers, Lung Cancer
    Watch Time: 15 mins
    touchFOCUS
    Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
    CE/CME ACCREDITED Dr Dana Chase

    Watch Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment.

    Learning objectives
    Learning Objectives
    • Discuss the implications of tumour-agnostic approaches in oncology and the role of tumour-agnostic biomarkers, such as HER2, across solid tumour types
    • Evaluate the use of HER2 as a tumour-agnostic biomarker in expanding the application of HER2-targeted therapies across various HER2-positive cancers
    Colorectal Cancer, Gastrointestinal Cancers
    Munich Germany
    Highlights from ESMO GI 2024

    The ESMO GI 2024 meeting, held this year in Munich, Germany, brought together researchers and clinicians from around the world to discuss recent developments in gastrointestinal malignancies.

    Colorectal Cancer, Gastrointestinal Cancers
    Key data in gastrointestinal cancer: ESOPEC, TRANSMET, COLLISION, ARC-9
    Michael Cecchini Watch Time: 9 mins

    Practice-changing data in the field of gastrointestinal cancer was presented at ASCO 2024. To understand these, as well as the other highlights from the meeting, we spoke with Assistant Professor of Medicine (Medical Oncology), Yale School of Medicine, Dr Michael Cecchini. In this interview, Dr Cecchini discusses the findings from the ESOPEC (NCT02509286), TRANSMET (NCT02597348), COLLISION (NCT03088150), ARC-9 (NCT04660812), ABBV-400 (NCT05029882) and other presentations, offering his valuable insights into the impact the results could have on clinical practice.

    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 42 mins
    touchIN CONVERSATION
    Harnessing the power of precision medicine for the treatment of colorectal cancer
    CE/CME ACCREDITED Dr Juan Manuel O’Connor, Prof. Dr Francesco Sclafani Translations available:

    Watch GI oncologists discuss navigating the biomarker landscape to implement personalized treatment in CRC.

    Learning objectives
    Learning Objectives
    • Recognize the importance of biomarker testing to inform treatment decisions in CRC
    • Evaluate the latest data for current and emerging therapies for the treatment of CRC
    • Apply strategies to address practical challenges in biomarker-targeted treatment of CRC
    Colorectal Cancer, Gastrointestinal Cancers
    Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer
    Tiago Biachi de Castria, Ruoyu Miao, Richard D Kim

    touchREVIEWS in Oncology & Haematology. 2024;20(1):20–24

    Outcomes for patients with metastatic colorectal cancer have steadily improve due to discovery of new drugs as well as increasing number patients undergoing local therapies.1 Angiogenesis is of a paramount importance in this disease and since vascular endothelial growth factor (VEGF) discovery several drugs targeting this pathway have been developed.2,3 Fruquintinib (HMPL-013) is a tyrosine kinase […]

    Colorectal Cancer
    Developed by Touch
    Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
    Watch Time: 6 mins

    The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key […]

    Colorectal Cancer, Gastrointestinal Cancers
    Developed by Touch
    Ben Weinberg, ASCO 2023: Highlights from the PROSPECT, AtezoTRIBE, D-ToRCH and DESTINY-CRC02 trials
    Watch Time: 9 mins

    touchONCOLOGY spoke with editorial board member Ben Weinberg (Georgetown University, Washington, DC, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. This includes data from the Plenary Session randomized phase 3 noninferiority PROSPECT trial, showing that neoadjuvant FOLFOX with selective use of 5-FU chemoradiotherapy (5-FU CRT) […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup